Your browser is no longer supported. Please, upgrade your browser.
NeoGenomics, Inc.
Index- P/E78.87 EPS (ttm)0.55 Insider Own2.70% Shs Outstand118.29M Perf Week3.88%
Market Cap5.35B Forward P/E- EPS next Y-0.16 Insider Trans-9.54% Shs Float117.84M Perf Month-8.44%
Income71.70M PEG6.41 EPS next Q-0.08 Inst Own93.00% Short Float6.30% Perf Quarter-0.75%
Sales488.70M P/S10.96 EPS this Y-51.70% Inst Trans-0.09% Short Ratio8.18 Perf Half Y-9.62%
Book/sh9.71 P/B4.47 EPS next Y23.80% ROA5.40% Target Price56.80 Perf Year-1.27%
Cash/sh4.63 P/C9.36 EPS next 5Y12.30% ROE8.60% 52W Range36.00 - 61.57 Perf YTD-19.43%
Dividend- P/FCF- EPS past 5Y23.30% ROI0.30% 52W High-29.11% Beta0.63
Dividend %- Quick Ratio7.10 Sales past 5Y34.80% Gross Margin42.20% 52W Low21.24% ATR2.21
Employees1700 Current Ratio7.30 Sales Q/Q39.90% Oper. Margin-5.60% RSI (14)44.97 Volatility3.14% 4.92%
OptionableYes Debt/Eq0.46 EPS Q/Q- Profit Margin14.70% Rel Volume0.66 Prev Close43.38
ShortableYes LT Debt/Eq0.46 EarningsAug 06 BMO Payout0.00% Avg Volume907.55K Price43.65
Recom1.60 SMA20-3.84% SMA50-5.69% SMA200-7.71% Volume602,127 Change0.62%
Oct-14-21Upgrade Raymond James Mkt Perform → Outperform $53
Jun-03-21Initiated Goldman Buy $55
Feb-25-21Resumed Needham Buy $65
Feb-25-21Downgrade Raymond James Outperform → Mkt Perform
Jan-28-21Initiated Truist Buy $65
Dec-11-20Resumed BTIG Research Buy $60
Oct-28-20Reiterated Needham Buy $39 → $46
Sep-09-20Initiated Morgan Stanley Overweight $46
Aug-28-20Initiated Guggenheim Buy $46
Jul-29-20Reiterated Needham Buy $33 → $39
Jun-25-20Initiated BofA/Merrill Buy $34
Apr-21-20Resumed Stephens Overweight $33
Mar-02-20Resumed Craig Hallum Buy $38
Feb-28-20Upgrade First Analysis Sec Outperform → Strong Buy
Jan-23-20Downgrade First Analysis Sec Strong Buy → Outperform $29 → $35
Oct-30-19Reiterated Needham Buy $27 → $29
May-01-19Reiterated Needham Buy $22 → $24
Mar-29-19Reiterated Needham Buy $19 → $22
Jan-03-19Initiated Needham Buy $14
Oct-24-18Upgrade First Analysis Sec Outperform → Strong Buy $18
Oct-13-21 04:20PM  
Oct-12-21 04:05PM  
Oct-01-21 01:13PM  
Sep-09-21 07:00AM  
Sep-06-21 01:14PM  
Sep-01-21 04:05PM  
Aug-23-21 08:56AM  
Aug-13-21 12:53PM  
Aug-06-21 05:30PM  
Jul-30-21 03:00PM  
Jul-14-21 04:05PM  
Jun-21-21 08:04AM  
Jun-18-21 10:34PM  
Jun-08-21 08:01AM  
May-27-21 04:05PM  
May-25-21 04:44AM  
May-18-21 12:33PM  
May-12-21 09:02AM  
May-11-21 09:11AM  
May-10-21 04:15PM  
May-09-21 08:30AM  
May-05-21 06:01PM  
Apr-28-21 12:34PM  
Apr-19-21 07:00AM  
Apr-16-21 05:15AM  
Apr-13-21 07:00AM  
Apr-07-21 04:05PM  
Apr-01-21 06:05AM  
Mar-24-21 10:04AM  
Mar-16-21 07:00AM  
Mar-01-21 07:00AM  
Feb-25-21 07:00AM  
Feb-24-21 02:30PM  
Feb-16-21 07:00AM  
Feb-05-21 07:00AM  
Feb-04-21 07:00AM  
Feb-02-21 08:00AM  
Jan-10-21 11:00AM  
Jan-06-21 11:00PM  
Jan-05-21 04:05PM  
Jan-04-21 07:30AM  
Dec-16-20 05:33PM  
Nov-29-20 06:44AM  
Nov-16-20 08:00AM  
Nov-13-20 04:05PM  
Nov-09-20 07:00AM  
Oct-29-20 09:34AM  
Oct-28-20 10:58AM  
Oct-27-20 02:00PM  
Oct-20-20 12:31PM  
Oct-15-20 09:00AM  
Oct-13-20 01:31PM  
Oct-01-20 07:00AM  
Sep-10-20 04:05PM  
Sep-07-20 11:40AM  
Aug-31-20 05:00PM  
Aug-28-20 10:16AM  
Aug-06-20 01:43PM  
Aug-05-20 11:11AM  
Jul-30-20 10:52AM  
Jul-28-20 01:30PM  
Jul-21-20 12:31PM  
Jul-20-20 07:00AM  
Jul-12-20 06:12AM  
Jul-04-20 08:18PM  
Jul-01-20 07:00AM  
Jun-29-20 07:00AM  
Jun-25-20 10:10AM  
Jun-18-20 12:27PM  
Jun-12-20 01:50AM  
Jun-10-20 06:44PM  
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CROWTHER BRUCE KDirectorJun 08Option Exercise14.5820,734302,24170,298Jun 10 05:01 PM
CROWTHER BRUCE KDirectorJun 08Sale41.4620,734859,63249,564Jun 10 05:01 PM
CARDOZA GEORGEPresident, Pharma ServicesJun 03Sale40.1131,1071,247,702176,772Jun 04 07:56 PM
CARDOZA GEORGEPresident, Pharma ServicesJun 02Sale40.39169,2306,835,200207,879Jun 04 07:56 PM
SHOVLIN ROBERT J.President, Clinical ServicesMay 25Option Exercise11.80126,9581,498,530280,705May 27 06:23 PM
SHOVLIN ROBERT J.President, Clinical ServicesMay 25Sale39.31130,6045,134,043150,101May 27 06:23 PM
Weiss Lawrence MartinChief Medical OfficerApr 22Option Exercise20.1125,050503,646130,847Apr 26 05:48 PM
JONES STEVEN CDirectorJan 07Option Exercise7.15100,000715,0001,100,000Jan 11 05:24 PM
JONES STEVEN CDirectorJan 07Option Exercise11.7917,286203,83590,218Jan 11 05:24 PM
Weiss Lawrence MartinChief Medical OfficerDec 14Option Exercise9.40109,0041,024,986120,721Dec 15 08:51 PM
Weiss Lawrence MartinChief Medical OfficerDec 14Sale51.0620,2001,031,412100,521Dec 15 08:51 PM
JONES STEVEN CDirectorDec 14Sale51.6725,0001,291,7501,000,000Dec 14 05:49 PM
BALLIET JENNIFERVP and Chief Culture OfficerDec 11Option Exercise8.0315,000120,45039,980Dec 11 05:57 PM
BALLIET JENNIFERVP and Chief Culture OfficerDec 11Sale49.9915,000749,85024,980Dec 11 05:57 PM
JONES STEVEN CDirectorDec 11Sale50.5225,0001,263,0001,025,000Dec 14 05:49 PM
JONES STEVEN CDirectorDec 10Sale50.3020,0001,006,0001,050,000Dec 14 05:49 PM
JONES STEVEN CDirectorDec 07Sale49.4545,6582,257,7881,070,000Dec 07 06:23 PM
Johnson Kevin CDirectorDec 04Sale47.8824,6831,181,82230,983Dec 07 06:19 PM
JONES STEVEN CDirectorDec 04Sale48.0764,3943,095,4201,115,658Dec 07 06:23 PM
JONES STEVEN CDirectorDec 03Sale48.0319,948958,1021,180,052Dec 07 06:23 PM
Bonello WilliamPresident, InformaticsDec 02Option Exercise8.038,00064,24020,060Dec 04 06:03 PM
Bonello WilliamPresident, InformaticsDec 02Sale46.808,000374,40012,060Dec 04 06:03 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 25Option Exercise7.5277,074579,596447,976Nov 25 06:04 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 25Sale45.4877,0743,505,326370,902Nov 25 06:04 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 24Option Exercise7.5272,926548,404423,828Nov 25 06:04 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 24Sale45.1952,9262,391,726370,902Nov 25 06:04 PM
VAN OORT DOUGLAS MChairman and CEONov 16Option Exercise7.5220,000150,4002,522,790Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 16Sale42.34100,0004,234,0002,422,790Nov 16 08:30 PM
HIPP RAYMOND RDirectorNov 16Sale42.2870,0002,959,60066,800Nov 18 06:53 PM
VAN OORT DOUGLAS MChairman and CEONov 13Option Exercise7.52358,7522,697,8152,621,542Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 13Sale41.56118,7524,935,3332,502,790Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 12Option Exercise7.52121,248911,7852,384,038Nov 16 08:30 PM
VAN OORT DOUGLAS MChairman and CEONov 12Sale42.18121,2485,114,2412,262,790Nov 16 08:30 PM
Pedulla Denise EGeneral CounselNov 10Option Exercise7.8515,000117,75058,988Nov 12 06:00 PM
Pedulla Denise EGeneral CounselNov 10Sale42.002,26295,00456,726Nov 12 06:00 PM